Skip to main content

Clinical Trials Using Anastrozole

Review the clinical trials studying anastrozole on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Status: Active
Location: 758 locations
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
Status: Active
Location: 604 locations
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Status: Active
Location: 57 locations
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Status: Active
Location: 43 locations
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Status: Active
Location: 41 locations
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Status: Active
Location: 39 locations
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Status: Active
Location: 26 locations
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Status: Active
Location: 24 locations
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Status: Active
Location: 17 locations
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Status: Active
Location: 17 locations
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Status: Active
Location: 13 locations
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Status: Active
Location: 14 locations
Studying the Effects of Removing Adjuvant Chemotherapy for the Treatment of Estrogen Receptor-Positive, HER2-Negative Breast Cancer in Patients with a Low-Genomic Risk, SELECT Trial
Status: Active
Location: 12 locations
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Status: Active
Location: 12 locations
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: Active
Location: 12 locations
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Status: Active
Location: 12 locations
Comparing Different Endocrine Therapies for Male Breast Cancer, ETHAN Trial
Status: Active
Location: 8 locations
Abemaciclib in Combination with Endocrine Therapy for the Treatment of Older Patients with Hormone Receptor Positive Metastatic Breast Cancer
Status: Active
Location: 6 locations
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Status: Active
Location: 3 locations
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
Trastuzumab Deruxtecan Alone, in Combination with Anastrozole, or Followed by Chemotherapy for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Status: Active
Location: 3 locations
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Status: Active
Location: 4 locations
Biomarker-Directed Approach to Guide Hormonal Therapy before Surgery for Patients with Stage II/III ER-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 2 locations
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Vaccine (MUC1 Peptide-Poly-ICLC) for the Treatment of Estrogen Receptor Positive Breast Ductal Carcinoma in Situ
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania